Insurance denials and delays in care for pediatric patients with inflammatory bowel disease

Biologics are effective medications used for induction and maintenance of remission in pediatric patients with inflammatory bowel disease (IBD). Insurance companies often require clinicians to obtain prior authorization (PA) prior to administration of biologics. Recent data determined that PA was associated with delays in care in pediatric IBD patients and an increased risk of subsequent healthcare utilization. Our study aim was to assess the effect of the PA process and its impact on care delivery for pediatric patients with IBD.

Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Pareenaz Behbahani-Nejad, Michael Finkler, Hasina Momotaz, Sharon Perry, Denise Young, Thomas Sferra, Jonathan Moses Source Type: research